ABSTRACT: Testosterone is converted to 5 a-dihydrotestosterone (DHT) by 5 a-reductase enzyme, which is encoded by the SRD5A2 gene. DHT is the main androgen responsible for prostate growth. We have analyzed the complete coding region of the SRD5A2 gene in 87 histologically confirmed prostate cancer (PC) patients, 40 benign prostatic hyperplasia (BPH) cases, and 96 control samples from southern parts of India. The study revealed the A49T site to be monomorphic, the V89L site to be highly polymorphic, and the (TA) n repeat site to be polymorphic with only 2 alleles in our populations. The distribution of V89L alleles between PC cases and controls was not significantly different; however, (TA) 9 alleles distributed differently between the 2 groups. BPH cases exhibited alleles similar to controls at all polymorphic sites. The sequencing of the whole coding region did not reveal any other known or novel polymorphism in this gene. Our study emphasizes that the (TA) 9 allele might confer certain PC risk but that A49T and V89L polymorphisms do not confer PC risk in South Indian men.
P
rostate cancer (PC) is the most common form of cancer in males and the second most common cause of cancer leading to death (Jemal et al, 2008) . Benign prostatic hyperplasia (BPH) is the most common urological condition in elderly men. BPH is not associated with PC; however, men can have both PC and BPH (Ziada et al, 1999) . The incidence of PC increased in the American population in the late 1980s and early 1990s. A similar increase has also been observed in low-risk countries like India (Srinivas et al, 1995) . The occurrence of PC demonstrates familial aggregation, with a 2-to 4-fold increased risk among men reporting PC in a father or brother after adjustment for age and dietary factors (Heinlein and Chang, 2004) . Androgens (testosterone and 5 a-dihydrotestosterone) are actively involved in prostate development (Heinlein and Chang, 2004) . Approximately 80%-90% of prostate cancers are dependent on androgens at initial diagnosis, and endocrine therapy of PC is directed toward the reduction of serum androgens and inhibition of androgen receptor (AR) (van der Kwast et al, 1991) . Therefore, the AR gene has been studied extensively in PC, and polymorphisms in the AR gene have been associated with PC risk (for review see Rajender et al, 2007) .
Testosterone, after entering into the target cells, is converted to the more potent androgen dihydrotestosterone (DHT) by the action of the enzyme, 5 a-reductase (Wilbert et al, 1983; Coffey, 1993) . DHT is mainly responsible for prostate growth, and it has been demonstrated that the tissue DHT level is a useful marker in predicting the clinical response of prostate cancer to anti-androgen therapy (Geller et al, 1984) . The levels of DHT and resulting androgen action vary among different individuals depending on the activity of 5 a-reductase. Ross et al (1992) demonstrated that young Japanese men have lower 5 a-reductase activity than young Caucasian American and African American men. Similarly, Wu et al (1995) reported that the DHT:testosterone ratio was highest in African Americans, intermediate in Caucasians, and lowest in Asian Americans, corresponding to the respective risk of developing PC in these groups. Taking the above into consideration, it has been hypothesized in several studies that the polymorphisms in the SRD5A2 gene could affect PC risk (Kantoff et al, 1997; Lunn et al, 1999; Hsing et al, 2001; Latil et al, 2001) .
The human SRD5A2 gene, mapped on chromosome 2 (2p23), has 5 exons and 4 introns and encodes the enzyme 5 a-reductase, expressed in androgen-dependent tissues (Thigpen et al, 1993) . A number of mutations/ polymorphisms have been identified in the SRD5A2 gene; however, A49T, V89L, and (TA) n repeat polymorphisms are the most frequent. Most of the study till date have analyzed only A49T, V89L single-nucleotide polymorphisms, and (TA) n polymorphic repeat regions. Controversies exist regarding the association of these polymorphisms with PC risk (Ntais et al, 2003) . The meta-analyses are of immense use in such situations to resolve controversies; however, the bias in the publication of the studies showing positive correlation rather than no correlation might make the meta-analysis less transparent. To assess the correlation more judiciously, the studies finding no significant correlation of the polymorphism(s) with the disorder should also be brought forward, and an effort should be made to generate data on various populations of the world. This study is such an effort. We analyzed the SRD5A2 gene for mutations/polymorphisms in Indian PC patients. To the best of our knowledge, no previous study has analyzed the full coding region of the SRD5A2 gene among Indian prostate cancer patients. We have undertaken sequencing of the full coding region and a part of the 39 UTR region encompassing the (TA) n repeat of the SRD5A2 gene to understand the role of SRD5A2 polymorphisms in disease risk and to assess the racial and ethnic differences from other populations of the world (Table 1) .
Materials and Methods

Subjects
The study included 87 histologically confirmed PC cases, 40 BPH patients, and 96 male control subjects from the southern parts of India. The control comprised healthy individuals with normal serum PSA levels of 4 ng/mL of blood or less (reference level, ,4 ng/mL), with no previous history of cancer, which was confirmed by digital rectal examination. BPH patients had normal serum PSA levels (#4 ng/mL) and were examined by digital rectal examination to confirm enlarged prostate. However, no histology could be done for the BPH group because of the lack of biopsy. All cases and controls were enrolled under informed written consent. The patients and controls were enrolled from a population with the same ethnic origin. Relevant clinical and pathological data were collected for all the patients. In PC patients age ranged from 45 to 98 years, with a mean age of 67.5 years; 55-77 years with a mean of 65.5 years in BPH patients, and 50-81 years with a mean of 66.5 years in normal healthy controls. Pathological grading of the tumors by Gleason scores was obtained, and the patients were classified as low grade if their Gleason scores were less than 7 and high grade if their Gleason scores were greater than or equal to 7. The Gleason score was less than 7 in 48 patients and greater than or equal to 7 in 39 patients. The study was approved by the ethical committee of the Institute. 
Genetic Analysis of SRD5A2 Gene
Genomic DNA was isolated from peripheral blood lymphocytes by the method described in our earlier study (Thangaraj et al, 2002) . The primers used for polymerase chain reaction (PCR) amplification of the SRD5A2 gene, including intron/ exon junctions, were designed with GeneTool software and synthesized with the use of a 394 DNA/RNA oligosynthesizer (Applied Biosystems, Foster City, California). Conditions for PCR amplification along with primer sequences for each exon are detailed in Table 2 . The PCR products were sequenced directly by the dideoxy cycle sequencing chain termination method (Big Dye V3.1, Applied Biosystems) on an ABI 3730 DNA analyzer (Thangaraj et al, 2003) . Sequence editing and multiple alignments were carried out with AutoAssembler software (Applied Biosystems). The sequencing signal for the V89L polymorphism was not clear at the polymorphic site despite repeated efforts; therefore, this polymorphism was typed by PCR restriction fragment length polymorphism (PCR-RFLP). The restriction reaction included a 10-mL PCR product, 2 units of RsaI restriction enzyme, 10 mL of restriction buffer, and incubation at 37uC for 1 hour. After restriction digestion, the reaction mixture was run on 10% PAGE to see the banding pattern. For distinguishing the homozygous and heterozygous genotypes at the (TA) 9 repeat, we amplified this region with the FAM (carboxyfluorescein)-labeled forward primer (Table 2 ) and genotyped it with 3730 DNA analyzer. For genotyping, 3.0 mL of PCR product was mixed with 0.3 mL of LIZ size standard (Applied Biosystems) and 6.7 mL of Hi-Di formamide (Applied Biosystems). Before running on the DNA analyzer, the mixture was heated to 95uC for 5 minutes, followed by cooling on ice for 5 minutes.
Statistical Analyses
We calculated the allelic percentages for SRD5A2 polymorphisms and analyzed them for differences between cases and controls. Because it is known that the SRD5A2 allele with valine (Val) at the V89L polymorphic site confers high activity to the enzyme compared with the allele with leucine (Leu) (Makridakis et al, 2000) , the genotypes at this site were named high-activity (Val/Val) and low-activity (Val/Leu and Leu/Leu) genotypes. The high-and low-activity genotypes were analyzed for differences between cases and controls. The test was performed for PC vs controls and BPH vs controls, independently. We used the chi-square (x 2 ) test to calculate the significance of differences between cases and controls. Chisquare values were calculated with the online Vassar Stats Calculator (http://faculty.vassar.edu/lowry/VassarStats.html). Two-sided P values of less than .05 were taken to be significant. We analyzed the frequency distribution of various genotypes at the V89L polymorphic site with respect to various clinical parameters using SPSS software (version 11; SPSS Inc, Chicago, Illinois). Furthermore, different alleles at the V89L and (TA) n polymorphic sites were examined for linkage disequilibrium in both the cases and the controls.
Results
We did not observe any polymorphism at the A49T polymorphic site (Table 3) . PC, BPH, and control samples invariably had the wild-type allele (A) at this site. The V89L site was highly polymorphic ( Figure 1) ; however, the differences in the frequency distribution of various alleles/genotypes at this site were not significant between PC cases and controls or BPH and controls ( Table 3) . For genotype analyses, the Val/Val genotype was considered to be a high-activity genotype, whereas Val/Leu and Leu/Leu were considered to be low-activity genotypes. We did not find any difference between cases and controls in the distribution of high-and low-activity genotypes (Table 4) . At the (TA) n repeat site, we observed the (TA) 0 allele to be the most common in both the cases (97.7%) and the controls (100%), whereas (TA) 9 occurred at a very low frequency (2.3%) among the PC cases only (Table 3) . PC cases exhibited all 3 possible genotypes at the (TA) n site, with a maximum frequency (96.55%) of (TA) 0 /(TA) 0 , a low frequency (2.3%) of (TA) 0 /(TA) 9 , and an even lower frequency (1.15%) of (TA) 9 /(TA) 9 (Table 4 Figure 2 ). No other parameter correlated positively or negatively with the V89L polymorphic site. BPH cases possessed alleles and genotypes similar to the control samples at all the 3 polymorphic sites.
Discussion
Testosterone and its metabolite DHT are crucial for growth and development of prostate gland. The research a The x 2 and the respective P values for the V89L polymorphism were calculated for PC cases vs control and for BPH cases vs controls separately. For this purpose, the 3 genotypes at this site were classified into 2 groups for both the cases and the controls: high activity (Val/Val) and low activity (Val/Leu and Leu/Leu).
on PC has focused mainly on the genes related to androgen action. In this study, we have sequenced the entire coding region and 39 UTR region encompassing the (TA) n repeat of the SRD5A2 gene in 87 PC cases, 40 BPH cases, and 96 control samples. Most of the studies on the SRD5A2 gene in PC have focused only on these 3 polymorphisms (A49T, V89L, and [TA] n repeat). We have for the first time analyzed the entire coding sequence. The study revealed no polymorphism at the A49T locus. Differences in the distribution of (TA) n alleles but not V89L alleles were observed between the cases and the controls. Earlier studies on these polymorphisms in SRD5A2 have shown contradictory results. However, a meta-analysis has shown no significant association of any of these polymorphisms with prostate cancer susceptibility (Ntais et al, 2003) . More studies might help to resolve the controversy regarding the association of genetic variations in the SRD5A2 gene with PC risk.
We observed no polymorphism at the A49T locus. All PC, BPH, and control samples had A at this site. A49T has been one of the most commonly studied polymorphisms in the SRD5A2 gene. The A49T variant (Ala 49 Thr substitution) has been linked to pathological characteristics of PC (Jaffe et al, 2000) . It increases the activity of the steroid 5-a-reductase enzyme by 5-fold. The T variant has been found to be more prevalent in Caucasians (3.5%) than African Americans, Asians, or Hispanics (Jaffe et al, 2000) . An A49T amino acid substitution increased the risk of clinically significant disease by 7.2-fold in African American men (95% confidence interval [CI], 2.17-27.91; P 5 .001) and 3.6-fold in Hispanic men (CI, 1.09-12.27; P 5 .04). The polymorphism was reported to increase PC risk, and the mutant enzyme had a higher in vitro V max than the normal enzyme (9.9 compared with 1.9 nmolmin 21 mg 21 ; Makridakis et al, 1999) . This polymorphism has been reported among Caucasian men and Asians but showed no association with PC risk (Latil et al, 2001; Mononen et al, 2001; Soderstrom et al, 2002) . Earlier studies on Japanese (Yamada et al, 2001 ) and Chinese men (Hsing et al, 2001 ) also demonstrated monomorphism at the A49T locus. Taking our results into account, it appears that Asian or, more narrowly, South Asians have similar alleles (A) at this locus, which might signify their genetic affinities. Indian men thus carry a low-risk allele at this locus compared with Caucasians, African Americans, and Hispanics. Nevertheless, it is very important to generate similar data for other Indian and South Asian populations to strengthen or refute the above statement.
We observed the V89L site to be highly polymorphic, but no significant difference was observed between PC cases and controls or BPH and control samples. The V89L substitution occurs at a frequency of 8.5% in Caucasians, 2.5% in African Americans, and 28% in Taiwanese men (Nwosu et al, 2001) . The V89L polymorphism is more common than the A49T, at around 30% frequency (Febbo et al, 1999; Jaffe et al, 2000; Makridakis et al, 2000) . It has been shown that the distribution of V89L genotypes parallels the patterns of PC incidence in high-and low-risk populations, with an Leu/Leu genotype prevalence of 22%-25% among Asians and of only about 4% among Caucasian and African Americans, and a Val/Val genotype prevalence of 27%-29% among Asians and about 58% among African and Caucasian Americans (Makridakis et al, 1999; Ross et al, 1992; Yamada et al, 2001) . Similarly, Nam et al (2001) have claimed a 3.3-fold increased risk of disease recurrence with the Val/Val and Val/Leu genotypes in Canadian populations. The results of the above studies are supported by in vitro studies showing that, compared with the Val/Val genotype, the Leu/Leu genotype confers a 42% reduction in 5 a-reductase enzymatic activity (Makridakis et al, 2000) . Conversely, other studies on French (Cussenot et al, 2007) and Swedish populations (Giwercman et al, 2005) reported that the Leu/Leu genotype is associated with PC risk. This polymorphism has not found significant association with PC risk among Caucasian men (Febbo et al, 1999; Lunn et al, 1999) and in Japanese men (Yamada et al, 2001 ). Similar to the above studies, we did not observe any difference in the distribution of V89L alleles/genotypes between cases and controls. An earlier study of a North Indian population also reported no association of the V89L polymorphism with PC risk (Sobti et al, 2006) . In all the studies on South Asian populations, no association was detected with the V89L polymorphism; however, contradicting results are evident from studies on other populations (Table 1) .
The (TA) n repeat site has been relatively less studied. Since identification of the (TA) n repeat polymorphism, 3 major alleles have been reported-(TA) 0 , (TA) 9 , and (TA) 18 -with (TA) 0 being the most common in most of the populations (Akalu et al, 1999) . The observation that the rare (TA) 18 allele is limited to African American populations (Reichardt et al, 1995) , who have a higher rate of prostate cancer than Asian American or Caucasian men (Parkin et al, 1997) , suggests that a longer allele might be associated with increased enzyme activity. The relevance of the (TA) n marker in prostate cancer is further supported by the finding that 56% of 30 prostate tumors possessed somatic mutations at this locus (Akalu et al, 1999) . Thus, polymorphism at this locus might increase the risk of prostate cancer. We observed the (TA) 9 allele in 2.3% of the cases, although the frequency was too low to lay a strong association with PC risk (Table 3 ). In contrast, certain case control studies in Caucasian and Asian men have not found the (TA) 9 variant to be associated with an increased prostate cancer risk (Kantoff et al, 1997; Hsing et al, 2001; Latil et al, 2001) . In a few other studies, the longer (TA) n was not found to be associated with increased prostate cancer risk (Kantoff et al, 1997; Hsing et al, 2001; Latil et al, 2001 ). The longest allele, (TA) 18 , was found exclusively in African Americans, who are at increased risk of prostate cancer (Reichardt et al, 1995) . In accordance with the above observation, the (TA) 18 allele was absent from our cases as well controls.
A49T and V89L polymorphisms are present in the coding regions of the SRD5A2 gene and hence affect the enzyme activity by amino acid substitutions. But the (TA) n repeat is located in the 39 UTR of the SRD5A2 gene; therefore, it is unlikely to affect the structure or function of the resulting protein. However, it has been proposed that this polymorphism might influence regulation of 5 a-reductase enzyme production (Reichardt et al, 1995; Kantoff et al, 1997) , probably by altering mRNA stability (Zubiaga et al, 1995) . As a result, this polymorphism might alter DHT levels and consequently the risk of developing PC (Reichardt et al, 1995) . However, currently no study has addressed length of the (TA) n repeat in concert with intraprostatic levels of DHT. Out of 14 studies listed in Table 1 , only 5 (35.71%) have analyzed the A49T polymorphism, 12 (85.71%) have analyzed the V89L polymorphism, and only 3 (21.43%) have analyzed the (TA) n repeat. Only 2 studies (14.28%) have analyzed all 3 polymorphisms discussed above. Contrasting results for the A49T and V89L polymorphisms in our populations and the PC risk associated with longer (TA) n alleles emphasize the need to analyze the (TA) n repeat polymorphism in addition to A49T and V89L polymorphisms in further studies on this gene. Nevertheless, no study to date has analyzed the effect of the environment, if any.
Our study revealed monomorphism at the A49T locus and polymorphisms at the V89L and (TA) n sites. Inference on the basis of other populations indicates that our population carries a low-risk allele at the A49T site. Different variants at the V89L locus were almost equally frequent and conferred no PC risk. We found that the presence of the (TA) 9 allele might confer a PC risk; however, the difference was small. As observed in other populations, the (TA) 18 allele was absent from our samples, which could be for ethnic reasons. Sequence analysis of the whole coding region of the SRD5A2 gene did not reveal any other known or novel polymorphism. Therefore, it seems that V89L and (TA) n are the major polymorphic sites in the SRD5A2 gene in our population. The allelic variations in BPH were similar to controls at the (TA) n site, but the absence of longer (TA) n alleles in BPH cases cannot be ascertained given the lesser number of these cases in this study. The limitation of the sample size and certain variations in the percentage of various alleles on increasing the sample size cannot be denied. Our study emphasizes that A49T and V89L are not useful markers to use to estimate PC risk in Indian men, but the (TA) 9 repeat might be associated with PC risk to a certain extent; however, the low frequency limits any diagnostic value of this polymorphism. Therefore, it is clear from our study that the polymorphic status of the SRD5A2 gene is entirely different in Indian populations. We strongly suggest analysis of the SRD5A2 gene in more populations to clearly understand the conflicting observations regarding the association of A49T, V89L, and the (TA) n repeat polymorphisms with PC risk.
